| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pathophysiology,
Division of Pulmology, Department of Internal Medicine IV, and
Division of Hematology and Hemostaseology, Department of Internal Medicine I,
Department of Otorhinolaryngology, Vienna General Hospital, AKH, Medical University of Vienna, Vienna, Austria;
¶
Institute of Chemistry, University of Graz, Graz, Austria;
||
Allergy Unit, National Health Service, Rome, Italy; and
#
Institute of Chemistry and Biochemistry, University of Salzburg, Salzburg, Austria
The grass pollen allergen, Phl p 7, belongs to a family of highly cross-reactive calcium-binding pollen allergens. Because Phl p 7 contains most of the disease-eliciting epitopes of pollen-derived calcium-binding allergens, hypoallergenic variants were engineered according to the x-ray crystal structure of Phl p 7 for allergy vaccination. In three recombinant variants, amino acids essential for calcium binding were mutated, and two peptides comprising the N- and C-terminal half were obtained by synthetic peptide chemistry. As determined by circular dichroism analysis and size exclusion chromatography coupled to mass spectrometry, recombinant mutants showed altered structural fold and lacked calcium-binding capacity, whereas the two synthetic peptides had completely lost their structural fold. Allergic patients’ IgE Ab binding was strongest reduced to the variant containing two mutations in each of the two calcium-binding sites and to the peptides. Basophil histamine release and skin test experiments in allergic patients identified the peptides as the vaccine candidates with lowest allergenic activity. Immunization of rabbits with the peptides induced IgG Abs that blocked allergic patients’ IgE binding to Phl p 7 and inhibited allergen-induced basophil degranulation. Our results indicate that disruption of an allergen’s three-dimensional structure represents a general strategy for the generation of hypoallergenic allergy vaccines, and demonstrate the importance of allergen-specific IgG Abs for the inhibition of immediate allergic symptoms.
This article has been cited by other articles:
|
|
 |
|
  P. Verdino, R. Barderas, M. Villalba, K. Westritschnig, R. Valenta, R. Rodriguez, and W. Keller Three-Dimensional Structure of the Cross-Reactive Pollen Allergen Che a 3: Visualizing Cross-Reactivity on the Molecular Surfaces of Weed, Grass, and Tree Pollen Allergens J. Immunol., February 15, 2008; 180(4): 2313 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Westritschnig, B. Linhart, M. Focke-Tejkl, T. Pavkov, W. Keller, T. Ball, A. Mari, A. Hartl, A. Stocklinger, S. Scheiblhofer, et al. A Hypoallergenic Vaccine Obtained by Tail-to-Head Restructuring of Timothy Grass Pollen Profilin, Phl p 12, for the Treatment of Cross-Sensitization to Profilin J. Immunol., December 1, 2007; 179(11): 7624 - 7634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vrtala, M. Focke, J. Kopec, P. Verdino, A. Hartl, W. R. Sperr, A. A. Fedorov, T. Ball, S. Almo, P. Valent, et al. Genetic Engineering of the Major Timothy Grass Pollen Allergen, Phl p 6, to Reduce Allergenic Activity and Preserve Immunogenicity J. Immunol., August 1, 2007; 179(3): 1730 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Linhart, S. Bigenzahn, A. Hartl, C. Lupinek, J. Thalhamer, R. Valenta, and T. Wekerle Costimulation Blockade Inhibits Allergic Sensitization but Does Not Affect Established Allergy in a Murine Model of Grass Pollen Allergy J. Immunol., March 15, 2007; 178(6): 3924 - 3931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gafvelin, S. Parmley, T. Neimert-Andersson, U. Blank, T. L. J. Eriksson, M. van Hage, and J. Punnonen Hypoallergens for Allergen-specific Immunotherapy by Directed Molecular Evolution of Mite Group 2 Allergens J. Biol. Chem., February 9, 2007; 282(6): 3778 - 3787. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
